COLOPLAST SP.ADR 1/10 DK1 (CBH) - Net Assets
Based on the latest financial reports, COLOPLAST SP.ADR 1/10 DK1 (CBH) has net assets worth €13.80 Billion EUR (≈ $16.14 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€48.80 Billion ≈ $57.05 Billion USD) and total liabilities (€34.99 Billion ≈ $40.91 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check COLOPLAST SP.ADR 1/10 DK1 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.80 Billion |
| % of Total Assets | 28.29% |
| Annual Growth Rate | 29.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 49.98 |
COLOPLAST SP.ADR 1/10 DK1 - Net Assets Trend (2021–2024)
This chart illustrates how COLOPLAST SP.ADR 1/10 DK1's net assets have evolved over time, based on quarterly financial data. Also explore COLOPLAST SP.ADR 1/10 DK1 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for COLOPLAST SP.ADR 1/10 DK1 (2021–2024)
The table below shows the annual net assets of COLOPLAST SP.ADR 1/10 DK1 from 2021 to 2024. For live valuation and market cap data, see CBH company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | €17.94 Billion ≈ $20.98 Billion |
+3.72% |
| 2023-09-30 | €17.30 Billion ≈ $20.22 Billion |
+108.62% |
| 2022-09-30 | €8.29 Billion ≈ $9.69 Billion |
+1.52% |
| 2021-09-30 | €8.17 Billion ≈ $9.55 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COLOPLAST SP.ADR 1/10 DK1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 184.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €15.39 Billion | 85.78% |
| Other Components | €2.55 Billion | 14.22% |
| Total Equity | €17.94 Billion | 100.00% |
COLOPLAST SP.ADR 1/10 DK1 Competitors by Market Cap
The table below lists competitors of COLOPLAST SP.ADR 1/10 DK1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KT&G Corp
KO:033780
|
$12.73 Billion |
|
McCormick & Company Incorporated
NYSE:MKC
|
$12.74 Billion |
|
Synnex Corporation
NYSE:SNX
|
$12.76 Billion |
|
Penumbra Inc
NYSE:PEN
|
$12.76 Billion |
|
Winbond Electronics Corp
TW:2344
|
$12.73 Billion |
|
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
|
$12.72 Billion |
|
Goertek Inc
SHE:002241
|
$12.71 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
$12.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COLOPLAST SP.ADR 1/10 DK1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,299,000,000 to 17,942,000,000, a change of 643,000,000 (3.7%).
- Net income of 5,052,000,000 contributed positively to equity growth.
- Dividend payments of 4,720,000,000 reduced retained earnings.
- New share issuances of 500,000,000 increased equity.
- Other factors decreased equity by 189,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.05 Billion | +28.16% |
| Dividends Paid | €4.72 Billion | -26.31% |
| Share Issuances | €500.00 Million | +2.79% |
| Other Changes | €-189.00 Million | -1.05% |
| Total Change | €- | 3.72% |
Book Value vs Market Value Analysis
This analysis compares COLOPLAST SP.ADR 1/10 DK1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | €38.38 | €5.50 | x |
| 2022-09-30 | €39.06 | €5.50 | x |
| 2023-09-30 | €77.00 | €5.50 | x |
| 2024-09-30 | €79.62 | €5.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COLOPLAST SP.ADR 1/10 DK1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.16%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.69%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.68x
- Recent ROE (28.16%) is below the historical average (42.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 59.07% | 24.84% | 1.23x | 1.94x | €4.01 Billion |
| 2022 | 56.75% | 20.84% | 0.60x | 4.52x | €3.88 Billion |
| 2023 | 27.65% | 19.52% | 0.51x | 2.78x | €3.05 Billion |
| 2024 | 28.16% | 18.69% | 0.56x | 2.68x | €3.26 Billion |
Industry Comparison
This section compares COLOPLAST SP.ADR 1/10 DK1's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,324,600,777
- Average return on equity (ROE) among peers: -102.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | €13.80 Billion | 59.07% | 2.53x | $12.73 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $16.46 Billion |
| MEDIMI AB AK (79T) | $332.69K | -959.52% | 4.12x | $427.04K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-1.31 Million | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $831.06 Million |
| Carl Zeiss Meditec AG (AFX) | $797.45 Million | 7.81% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.06 Billion | 8.69% | 0.65x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.55 Million | -51.89% | 1.13x | $5.32 Million |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $93.24 Billion |
About COLOPLAST SP.ADR 1/10 DK1
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more